Education
About Us
Working with TipRanks
Follow Us
AIM ImmunoTech (AIM)
:AIM
AIM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.33 - $36.27
Previous CloseN/A
Volume272.06K
Average Volume (3M)63.98K
Market Cap
$6.91M
Enterprise Value$8.54M
Total Cash (Recent Filing)$835.00K
Total Debt (Recent Filing)$2.81M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Nov 14, 2025EPS Estimate
-0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.68
Shares Outstanding2,708,688
10 Day Avg. Volume43,494
30 Day Avg. Volume63,980
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue70.56
Enterprise Value/Gross Profit59.29
Enterprise Value/Ebitda-0.56
Forecast
1Y Price Target
$6.00Price Target Upside135.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Analyst RatingThe analyst maintains a BUY rating for AIM, seeing large upside opportunities that balance high risks with high growth prospects.
Clinical TrialsPositive data from a Phase 2 study for Ampligen as a therapeutic for patients with post-COVID conditions could boost stock performance.
Bears Say
Corporate GovernanceDissident stockholders have nominated their own slate of directors for the third consecutive year, indicating potential ongoing governance challenges.
Stock ListingThe company's stock has been delisted from NYSE American and is now trading on Pink Open Market, which might impact investor confidence.
AIM ImmunoTech News
AIM FAQ
What was AIM ImmunoTech’s price range in the past 12 months?
AIM ImmunoTech lowest stock price was $2.33 and its highest was $36.27 in the past 12 months.
What is AIM ImmunoTech’s market cap?
AIM ImmunoTech’s market cap is $6.91M.
When is AIM ImmunoTech’s upcoming earnings report date?
AIM ImmunoTech’s upcoming earnings report date is Nov 14, 2025 which is in 55 days.
How were AIM ImmunoTech’s earnings last quarter?
AIM ImmunoTech released its earnings results on Aug 15, 2025. The company reported -$3.68 earnings per share for the quarter, beating the consensus estimate of -$8 by $4.32.
Is AIM ImmunoTech overvalued?
According to Wall Street analysts AIM ImmunoTech’s price is currently Undervalued.
Does AIM ImmunoTech pay dividends?
AIM ImmunoTech pays a N/A dividend of $0.272 which represents an annual dividend yield of N/A. See more information on AIM ImmunoTech dividends here
What is AIM ImmunoTech’s EPS estimate?
AIM ImmunoTech’s EPS estimate is -0.97.
How many shares outstanding does AIM ImmunoTech have?
AIM ImmunoTech has 2,708,688 shares outstanding.
What happened to AIM ImmunoTech’s price movement after its last earnings report?
AIM ImmunoTech reported an EPS of -$3.68 in its last earnings report, beating expectations of -$8. Following the earnings report the stock price went up 3.113%.
Which hedge fund is a major shareholder of AIM ImmunoTech?
Currently, no hedge funds are holding shares in AIM
Company Description
AIM ImmunoTech
AIM ImmunoTech Inc. is a biotechnology company focused on developing innovative therapies for the treatment of various immune-related diseases and conditions. The company operates primarily in the biopharmaceutical sector, specializing in drug development for cancer and viral diseases. AIM's core product, Ampligen (rintatolimod), is an experimental therapeutic intended for use in various indications, including chronic fatigue syndrome and certain cancers, aiming to enhance the immune response.
AIM Stock 12 Month Forecast
Average Price Target
$6.00
▲(135.29% Upside)
Technical Analysis
Ownership Overview
64.41% Insiders
0.19% Mutual Funds
<0.01% Other Institutional Investors
35.39% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---